High-grade gliomas (World Health Organization grade III-IV) are highly lethal primary brain tumors. Imaging modalities, including MRI and FDG PET, provide a limited ability to differentiate treatment effects (such as radiation necrosis) from recurrent or residual tumor. As the first step in validating the applicability of prostate-specific membrane antigen (PSMA)-targeted imaging in high-grade gliomas, we evaluated the ability of the PSMA-targeted small molecule 
FIGURE 1.
MRI and 18 F-DCFPyL PET images demonstrate areas of presumed tumor involvement and normal brain. Three patients with findings on MRI highly suggestive of glioblastoma multiforme (GBM) were prospectively recruited and imaged with [ 18 F]DCFPyL. 1 Prostate-specific membrane antigen (PSMA) expression in tumor samples and normal brain tissue. Biopsy of the suspicious lesions, described above, demonstrated antibody staining correlating with 18 F-DCFPyL uptake. Normal brain tissue samples were used as a negative control. Staining was localized to tumor neovasculature in patients with GBM (patients 1 and 3) or tumor cells in anaplastic astrocytoma (patient 2). No staining was observed in normal brain or vessels. White arrow: blood vessels, asterisk: normal brain, X: anaplasia and high cellularity, black arrow: mitosis, red arrow: PSMA staining of anaplastic astrocytoma tumor cells. This is the first time a PSMA agent has imaged an anaplastic astrocytoma and the first time a GBM has been imaged with an 18 F-PSMA agent. Overall, the tested gliomas demonstrated increased radiotracer uptake when compared with background, as has been previously documented with other PSMA agents. 3, 4 Radiotracer uptakes for our patients were lower than what has been reported with 68 Ga-PSMA were SUV max ranged from 5.8 to 13.5. 4 The difference in uptake is nonconclusive as the biology of the tumors may be different or, less likely, based on our experience with other tumors, could be ascribed to the imaging agent. Regardless, the tumor-to-normal tissue uptake ratio was superb for a diagnostic imaging modality. Our histological findings also correlate to previously published data where PSMA expression has been seen in tumor cells of lower-grade gliomas, 5 whereas the expression for GBM has been mostly in the tumor neovasculature [5] [6] [7] with an exception. 8 As a conclusion, we found [ 18 F]DCFPyL binds PSMA in the neovasculature of GBM and in tumor cells of anaplastic astrocytoma. Additional prospective studies to validate the use of PSMA-targeted imaging in GBM and to address specific clinical questions such as the differentiation of radiation necrosis from recurrent or residual tumor may be in order.
